Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus PENICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus PENICILLIN VK.
CYCLAPEN-W vs PENICILLIN-VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
Penicillin VK inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
250-500 mg orally every 6-8 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections (e.g., streptococcal pharyngitis, skin infections).
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
0.5 hours (normal renal function); prolonged to 3-10 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal: 20-40% unchanged via tubular secretion; hepatic metabolism to penicilloic acid; biliary/fecal: minimal (<5%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic